CCO Independent Conference Coverage

2005 Annual Meeting of the European Association for the Study of the Liver*

April 13-17, 2005 | Paris, France

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

New Developments in HBV Treatment

Track 1 of 3

Program Director: Stephanos J. Hadziyannis, MD

Faculty:
		Yves Benhamou, MD, PhD Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Daniel Shouval, MD

Improving HCV Therapy

Track 2 of 3

Capsule Summaries

Expert Analysis

Program Director: Stephanos J. Hadziyannis, MD

Faculty:
		Stephanos J. Hadziyannis, MD Thierry Poynard, MD Stefan Zeuzem, MD

Hot Topics in Hepatology

Track 3 of 3

Capsule Summaries

Expert Analysis

Program Director: Stephanos J. Hadziyannis, MD

Faculty:
		Nezam H. Afdhal, MD, FRCPI Robert G. Gish, MD Brent A. Neuschwander-Tetri, MD

CCO Daily News (Not required for CME credit)

April 17, 2005

April 16, 2005

HCV genotype 5 has a similar response to peginterferon plus ribavirin as genotype 1

April 15, 2005

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.